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ABSTRACT 
Background: 
'ƌĂǀĞƐ ?disease can be treated with antithyroid drugs (ATDs), radioiodine or surgery. Use of 
definitive treatments (radioiodine or surgery) varies widely across centres. Specific clinical 
circumstances, local facilities, patient and clinician preferences and perceptions will affect choice 
of treatment. Detailed understanding of UK clinicians ?ǀŝĞǁƐĂŶĚƚŚĞŝƌƌĂƚŝŽŶĂůĞĨŽƌdifferent 
treatments is lacking. 
Aims: To study the preferences and perceptions of UK clinicians on the role of surgery and 
radioiodine ŝŶƚŚĞŵĂŶĂŐĞŵĞŶƚŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ? 
Methods: British dŚǇƌŽŝĚƐƐŽĐŝĂƚŝŽŶ ? ?d ? ? ?^ŽĐŝĞƚǇĨŽƌŶĚŽĐƌŝŶŽůŽŐǇ ? ?^& ?ĂŶĚ ?ƌŝƚŝƐŚ
ƐƐŽĐŝĂƚŝŽŶŽĨŶĚŽĐƌŝŶĞĂŶĚdŚǇƌŽŝĚ^ƵƌŐĞŽŶƐ ? ?d^ ?members were invited to complete an 
online survey examining their management decisions in 'ƌĂǀĞƐ ? disease and factors that 
influenced their decisions. 
Results: 158 responses from UK consultants were included. The ratio of physicians to surgeons 
was 11:5 and males to females was 12:4. Most clinicians would commence ATDs in uncomplicated 
first presentation of 'ƌĂǀĞƐ ? disease. A wide range of risk estimates on the effectiveness and risks 
of treatment was given by clinicians. Radioiodine was ƵƐĞĚŵŽƐƚĨƌĞƋƵĞŶƚůǇŝŶƌĞůĂƉƐĞĚ'ƌĂǀĞƐ ?
disease. However severe eye disease and pregnancy strongly influenced choice in favour of 
surgery. Surgeons underestimated the success of radioiodine (P<0.01) and were more likely to 
recommend thyroidectomy than physicians.  
Conclusions: This survey demonstrates significant variation in cliniciaŶƐ ?ƉĞƌĐĞƉƚŝŽŶƐŽĨƌŝƐŬƐŽĨ
ƚƌĞĂƚŵĞŶƚĂŶĚƚŚĞŝƌĐŚŽŝĐĞŽĨŵĂŶĂŐĞŵĞŶƚŽƉƚŝŽŶƐĨŽƌƌĞůĂƉƐĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ?dŚĞǀĂƌŝĂƚŝŽŶ
appeared to be dependent on patient and disease specific factors as well as physician experience, 
gender and speciality.   
 
Main messages 
x The survey demonstrates sSignificant variation in management of Graves ? disease across 
UK 
x Surgery was more likely to be recommended in patients with severe 'ƌĂǀĞƐ ?thyroid eye 
disease and pregnancy.  
x ůŝŶŝĐŝĂŶƐ ?ƉĞƌĐĞƉƚŝŽŶƐof effectiveness and risk of treatment options in Graves ?ĚŝƐĞĂƐĞ
varied widely.Physicians and Surgeons ?have different approaches to the management of 
relapsed 'ƌĂǀĞƐ ?disease.  
Research Questions 
 
 /ƐƌĞůĂƉƐĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞƚƌĞĂƚĞĚĂƉƉƌŽƉƌŝĂƚĞůǇ ?
x What are the outcomes (effectiveness and risks) following the use of various treatment 
options in are the actual risks of GgƌĂǀĞƐ ?ĚŝƐĞĂƐĞs management in the UK? 
x How does surgery compare with radio-iodine in the management of Graves ?ĚŝƐĞĂƐĞŽǀĞƌĂůů
and in specific subgroups? 
x Should there be nNational guidelines and would these improve in the UK for the 
ŵĂŶĂŐĞŵĞŶƚŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ in the UK? 
  
Formatted: (none)
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BACKGROUND 
'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞŝƐƚŚĞŵŽƐƚĨƌĞƋƵĞŶƚĐĂƵƐĞŽĨŚǇƉĞƌƚŚǇƌŽŝĚŝƐŵ in iodine-replete countries. The 
production of autoantibodies against the thyroid stimulating hormone receptor (TSH-receptor) 
results in hyperplasia and hypertrophy of thyroid follicles and subsequent increase in thyroxine 
synthesis and release. The clinical manifestations of Graves ? disease include those due to 
hyperthyroidism (such as tachycardia, weight loss, diarrhoea, menstrual irregularities and 
sweating) as well as those specific to Graves ? disease, including a diffuse goitre and signs and 
symptoms of infiltrative eye disease  (such as periorbital oedema, proptosis, ophthalmoplegia).  
 
Following a diagnosis of 'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ?antithyroid drugs (ATDs) including carbimazole and 
propylthiouracil are used to control hyperthyroidism. Although these are very effective, they are 
associated with high rates of relapse[1,2]. For patients with relapsed hyperthyroidism or disease 
uncontrolled with ATDs, alternative treatment options such as radioiodine (RAI) therapy and 
surgery (most commonly total thyroidectomy) are considered to offer definitive treatment; each 
with its risks and benefits. 
 
The precise indications for these options have been debated and management practices are 
varied, particularly in the uncomplicated patient[3].  Patient preference also plays a large role in 
the decision to undergo either surgery or radioiodine. The rates of success, complication rates, 
ƐĞǀĞƌŝƚǇŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ?ĂǀĂŝůĂďŝůŝƚǇŽĨůŽĐĂůĨĂĐŝůŝƚ ĞƐĂŶĚĞǆƉĞƌƚŝƐĞalso influence decision 
ŵĂŬŝŶŐ ?,ŽǁĞǀĞƌ ?ƚŚĞĐůŝŶŝĐŝĂŶ ?ƐĂƐƐĞƐƐŵĞŶƚŽĨƚŚĞƐĞĨĂĐƚŽƌƐĂŶĚƚŚĞŝƌƉĞƌĐĞƉƚŝŽŶƐĂŶĚ
preferences will inevitably iŶĨůƵĞŶĐĞƚŚĞƉĂƚŝĞŶƚ ?ƐĚĞĐŝƐŝŽŶĂŶĚƚŚĞĚĞĐŝƐŝŽŶŵĂŬŝŶŐƉƌŽĐĞƐƐ ? 
 
Previously published papers have demonstrated the wide variation in practice within Europe and 
the world relating togarding ƚŚĞƚƌĞĂƚŵĞŶƚŽĨƌĞůĂƉƐĞĚ'ƌĂǀĞƐ ?Ddisease. In 2000, Escobar-Jimenez 
et al[4] ƐƵƌǀĞǇĞĚŶĚŽĐƌŝŶĞƵŶŝƚƐŝŶ^ƉĂŝŶƚŽĞǆƉůŽƌĞƚŚĞŝƌŵĂŶĂŐĞŵĞŶƚŽĨƵŶĐŽŵƉůŝĐĂƚĞĚ'ƌĂǀĞƐ ?
disease and relapsed patients looking at factors that influenced their decision making. Vaidya et al 
[5] reported on a UK survey of 698 clinicians(2008) discussed 'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞmanagement in the 
UK in the year 2008, but the study focussed primarilymainly concentrated on the use of radio-
iodine with little information regarding surgical practice. 
^ŽŵĞƐƚƵĚŝĞƐŚĂǀĞĞǆƉůŽƌĞĚĐůŝŶŝĐŝĂŶƐ ?ǀŝĞǁƐŽŶƚŚĞŵĂŶĂŐĞŵĞŶƚŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞĂŶĚ have 
found significant variation in practices. In 2008 Vaidya et al[4] reported on a UK survey of 698 
consultants involved in the management of thyroid disease. Various scenarios were discussed. In 
an uncomplicated thyrotoxic patient, 80% chose ATDs, 19% radioiodine, and 0.4% thyroidectomy. 
However in the presence of active thyroid eye disease, no respondent chose radioiodine. In 
patients with inactive eye disease, 46% would give radioiodine with steroid cover, and 26% would 
give radioiodine without steroid cover. Although the study was comprehensive for matters 
regarding radioiodine therapy, there is limited information on surgical preference.  
 
In 2000, Escobar-Jimenez et al[5] reported the results of a survey of Endocrine units in Spain. Ten 
scenarios were presented, each of which varied in factors that could influence treatment. In 
ƉĂƚŝĞŶƚƐƉƌĞƐĞŶƚŝŶŐǁŝƚŚƵŶĐŽŵƉůŝĐĂƚĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ? ? ?A?ĐŚŽƐĞATDs as the initial treatment 
ĂŶĚ ?A?ƌĂĚŝŽŝŽĚŝŶĞ ?/ŶƉĂƚŝĞŶƚƐǁŝƚŚƌĞůĂƉƐĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ?61% of responders preferred 
radioiodine except in pregnancy where 12% would use surgery and the remainder would use a 
further course of ATDs.  
 
In 2011 a survey was conducted by Burch et al[3] to assess international practice in the diagnosis 
ĂŶĚŵĂŶĂŐĞŵĞŶƚŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞĂŵŽŶŐƐƚƉŚǇƐŝĐŝĂŶƐĂŶĚƐƵƌŐĞŽŶƐƵƐŝŶŐǀĂƌŝŽƵƐƐĐĞŶĂƌŝŽƐ ?dŚĞ 
vast majority of the respondents first case was of non-ĐŽŵƉůŝĐĂƚĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ?ƵƌŽƉĞĂŶ
responders chose between antithyroid drugs (85.7%), radioiodine (13.3%) and surgery (1%). This 
practice differed to North America where the choice of ATD, radioiodine and surgery were made 
in 40.5%, 58.6% and 0.9% respectively. In the presence of eye disease or pregnancy, antithyroid 
drugs and thyroidectomy were preferred to radioiodine.majority of respondents (92.2%) Of note, 
92.2% of the respondents were specialists in adult Endocrinology (92.2%), with only 0.6% in 
General Surgery and 2.2% in Nuclear Medicine[3]. This may have potentially influenced results in 
favour of medical treatment. In 2013, the same questionnaire as that used by Burch et al in 2011, 
was sent to the European Thyroid Association members [6]. They reported no significant changes 
from previous surveys conducted in Europe on the treatment of 'ƌĂǀĞƐ ? disease[7], but 
demonstratedongoing significant differences between North America and Europe[3]. In 
uncomplicated first presentation of 'ƌĂǀĞƐ ? disease, 83.8% of survey responders chose ATDs as 
first line treatment (similar to 1987 survey), 14.1% radioiodine and surgery in just 2.1%. Neither 
Both of these two studies papers did not addressed ƚŚĞŵĂŶĂŐĞŵĞŶƚŽĨƌĞůĂƉƐĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ? 
 
To date, there are no nationalcurrent British ŐƵŝĚĞůŝŶĞƐĨŽƌƚŚĞƚƌĞĂƚŵĞŶƚŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞornor 
any studies that explore the factors influencing choice of surgery and radioiodine in the definitive 
treatment of relapsed 'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞŝŶƚŚĞh<, particularly in the scenario of relapse. In addition, 
ĐůŝŶŝĐŝĂŶƐ ?ƉƌĞĨĞƌĞŶĐĞƐĂŶĚƉĞƌĐĞƉƚŝŽŶƐŽĨƐƵĐĐĞƐƐĂŶĚĐŽŵƉůŝĐĂƚŝŽŶƌĂƚĞƐin this scenario are, as 
yet, unexplored.  
 
The aim of this study was to survey the preferences and perceptions of UK clinicians on the role of 
surgery and RAI in the management of relapsed 'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ? 
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METHODS 
Between December 2013 and January 2014, a survey (see Appendix) was sent out to all Consultant 
members of the British Thyroid Association (BTA), Society of Endocrinology (SFE) and the British 
Association of Endocrine and Thyroid Surgeons (BAETS) involvĞĚŝŶƚŚĞƚƌĞĂƚŵĞŶƚŽĨ'ƌĂǀĞƐ ?
disease ?dŚŝƐǁĂƐĐŽŶĚƵĐƚĞĚƵƐŝŶŐƚŚĞŽŶůŝŶĞƚŽŽů ?ƐƵƌǀĞǇŵŽŶŬĞǇ ?ĐŽŵ ?and reminders sent 2 
weeks later. To ensure anonymity, no names or personal details were requested. Information on 
speciality, year of graduation in Medicine, county of practice and gender was collected to enable 
us to detect duplicate responses and to evaluate if any of these demographic differences 
influenced ĐůŝŶŝĐŝĂŶƐ ?ƉĞƌĐĞƉƚŝŽŶƐĂŶĚƉƌĞĨĞƌĞŶĐĞƐ ?dŚĞsurvey start times and IP addresses of 
respondents collected automatically were also used to detect duplicate responses made in error 
(ƐƵĐŚĂƐƉƌĞƐƐŝŶŐƚŚĞ “ƐƵďŵŝƚ ? button more than once).  
 
Clinical specialities surveyed included Endocrinology, Endocrine Surgery, Head & Neck Surgery as 
well as Nuclear Medicine. The survey consisted of initial questions establishing the responders ? 
status as UK consultants and then collecting information on speciality, geography, gender, year 
ƐŝŶĐĞŐƌĂĚƵĂƚŝŽŶ ?ĂŶĚƚŚĞŶƵŵďĞƌŽĨ'ƌĂǀĞƐ ?ƉĂƚŝĞŶƚƐƐĞĞŶƉĞƌǇĞĂƌ ?^ƵďƐĞƋƵĞŶƚƋƵĞƐƚŝŽŶƐ
ĞǆƉůŽƌĞĚƌĞĂƐŽŶƐĨŽƌĐŽŵŵĞŶĐŝŶŐdƐŝŶŶĞǁůǇĚŝĂŐŶŽƐĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞĂŶĚǁŚĂƚƉĂƚŝĞŶƚ
factors influencĞĚĐůŝŶŝĐŝĂŶƐ ?ĚĞĐŝƐŝŽŶƐŽŶĚĞĨŝŶŝƚŝǀĞƚƌĞĂƚŵĞŶƚŝŶƌĞůĂƉƐĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ?dŚĞ
side effects quoted to patients for either radioactive iodine or surgery and the clinicians ? 
perception of what risks influenced patient decision-making was also examined. The final question 
ĂƐŬĞĚǁŚĂƚƚŚĞĐůŝŶŝĐŝĂŶƐ ?ƉƌĞĨĞƌĞŶĐĞǁŽƵůĚďĞŝĨƚŚĞǇǁĞƌĞƚŚĞƉĂƚŝĞŶƚǁŝƚŚƌĞůĂƉƐĞĚ ?
ƵŶĐŽŵƉůŝĐĂƚĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ?
 
Questionnaires were completed on surveymonkey.com. The results were downloaded to a 
Microsoft Excel 2007 worksheet and exported to IBM SPSS version 21 statistical software for 
Formatted: Line spacing:  single
further analysis. Evaluation for potential duplicate or multiple entries was performed, as explained 
above. For incomplete surveys, available answers were included in the analysis. In questions 
where ranges or open text answers were given, certain assumptions were made. Data presented 
as ratios were changed to percentages. Averages were calculated for data presented as ranges, 
ƵŶůĞƐƐƚŚĞƌĂŶŐĞǁĂƐǀĞƌǇǁŝĚĞ ?ĨŽƌĞŐ ?A? ? ? ? ?/Ĩ “A? ?Žƌ M ?ǁĂƐƵƐĞĚƚŽĚĞƐcribe a value, 10% was 
added to or subtracted from the value. If two values were presented for different groups (i.e. male 
or female; young or old), the average was taken. If two values are given for immediate and later 
relapse, the total was taken (or the larger number if this was thought to incorporate those that 
have relapsed before). If personal results were presented alongside literature, the personal results 
were taken. If the response rates to first and second course of antithyroid drugs were presented, 
only the rates from the first course were included in the analysis. 
 
Data on gender, specialty, county, and other categorical or ordinal responses to questions were 
reported as frequencies or percentages.   Data on year since graduation, and other quantitative 
data were reported using median and range (as none of our quantitative variables were normally 
distributed). Answers in text were grouped into similar categories. For example, 30 responses 
related to voice (change in voice, vocal cord weakness, hoarseness, recurrent laryngeal nerve palsy 
etc.) and these ǁĞƌĞŐƌŽƵƉĞĚŝŶĂƐƉĞĐŝĨŝĐĐĂƚĞŐŽƌǇŽĨ ?ǀŽŝĐĞĐŚĂŶŐĞ ?ĨŽƌƐƵƌŐŝĐĂůĐŽŵƉůŝĐĂƚŝŽŶƐ ? 
dŚĞƌĞƐƉŽŶƐĞƐǁĞƌĞĐŽŵƉĂƌĞĚďǇƐƉĞĐŝĂůƚǇ ?ƌĞŐŝŽŶ ?ŐĞŶĚĞƌ ?ǀŽůƵŵĞŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞƐĞĞŶĂŶĚ
years since graduation where appropriate. Binary data between groups were compared using the 
WĞĂƌƐŽŶĐŚŝƐƋƵĂƌĞƚĞƐƚǁŝƚŚĐŽŶƚŝŶƵŝƚǇĐŽƌƌĞĐƚŝŽŶ ?Žƌ&ŝƐŚĞƌ ?ƐĞǆĂĐƚƚĞƐƚ ? ?ŽŶƚŝŶƵŽƵƐĚĂƚĂǁĂƐ
compared using the Mann-Whitney U test (for two groups) or Kruskal-Wallis test (for more than 
two groups). The significance was set at the 5% level (p=0.05).  
 
dŚĞƐƚƵĚǇƌĞĐĞŝǀĞĚĞƚŚŝĐĂůĂƉƉƌŽǀĂůĨƌŽŵƚŚĞhŶŝǀĞƌƐŝƚǇŽĨ^ŚĞĨĨŝĞůĚ ?Ɛ ?hŶŝǀĞƌsity Research Ethics 
ŽŵŵŝƚƚĞĞ ? ? 
 
 
RESULTS 
 
169 responses were received but 11 were excluded either for duplicate responses (n=4) or 
because the respondents were not practising consultants in the UK (n=7). The demographics of 
the respondents are displayed in Table 1. 
  
Table 1. Demographic features of clinicians who responded to the survey 
 
Demographic 
Subcategory Number (%) 
Gender (n=154) Male 115 (74.7%) 
Female 39 (25.3%) 
Specialty (n=158) Endocrinology 108 (68.4%) 
Surgery 50 (31.6%) 
Region (n=156) East Midlands 8 (5.1%) 
East of England 18 (11.5%) 
London 20 (12.8%) 
North East England 8 (5.1%) 
North West England 16 (10.3%) 
Northern Ireland 5 (3.2%) 
Scotland 17 (10.9%) 
South East England 21 (13.5%) 
South West England 15 (9.6%) 
Wales 5 (3.2%) 
West Midlands 6 (3.8%) 
Yorkshire and the Humber 17 (10.9%) 
sŽůƵŵĞŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞƐĞĞŶƉĞƌǇĞĂƌ
(n=156) 
Less than 10 16 (10.3%) 
10 to 30 61 (39.1%) 
More than 30 79 (50.6%) 
Note: regions grouped by Eurostat Nomenclature of Territorial Units for statistics (NUTS 1) 
  
 The median (range) time since graduation for the cohort (n=155) was 25 (12-43) years. The 
proportion of females was 28.6% in Endocrinology and 18.4% in Surgery. Regarding the rationale 
for initiating antithyroid drugs in patients with newly diagnosed GraveƐ ?ĚŝƐĞĂƐĞ, 60.2% of 
physicians and 63.6% surgeons commenced ATDs to make the patients euthyroid with subsequent 
remission expected on withdrawal of ATDs. 9.1% of surgeons, however, used ATDs in preparation 
to definitive surgery compared to only 1.9% of physicians.  38% and 27.3% of physicians and 
surgeons respectively answered they used ATDs for both definitive treatment as well as a bridge 
to surgery. Their reasons were patient preference (n=11), other comorbidities (n=7), presence of 
large goitre (n=7) or an older patient (n=7). All the physicians answered they would commence 
ATDs for the reasons discussed but over half of the (54%) either ĂŶƐǁĞƌĞĚ ?ƵŶƐƵƌĞ ?/ĂŵŶŽƚ
ŝŶǀŽůǀĞĚŝŶƚŚŝƐƐƚĂŐĞ ?Žƌleft the question unanswered. 
 
The second question determined the influence of clinical factors on recommendations for 
ĚĞĨŝŶŝƚŝǀĞƚƌĞĂƚŵĞŶƚŽĨƌĞůĂƉƐĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ. Overall, clinicians were more likely to 
recommend surgery than radioiodine in the presence of the factors mentioned other than mild 
eye disease. The influence of speciality on the recommendation for treatment in context of the 
described factors are summarised in a cluster bar chart (Figure 1). Surgeons were significantly 
more likely than physicians to recommend surgery in the presence of mild (p<0.001) and 
moderate eye disease (p=0.002), large goitre (p<0.001), children at work/home (p=0.011) and 
young women intending to start a family (p<0.001).  
 
Similar analyses  (Figure 2) ǁĞƌĞƉĞƌĨŽƌŵĞĚƚŽůŽŽŬĂƚƚŚĞŝŶĨůƵĞŶĐĞŽĨŐĞŶĚĞƌŽŶĐůŝŶŝĐŝĂŶƐ ?
preference for surgery or radioiodine. Female clinicians were significantly more likely than their 
male counterparts to recommend surgery in the presence of severe eye disease (p=0.017) and 
lactation (p=0.008) (data not shown). 
 
The experience of consultants (in terms of years since graduation) did not appear to influence 
ƉƌĞĨĞƌĞŶĐĞĨŽƌƌĂĚŝŽŝŽĚŝŶĞŽƌƐƵƌŐĞƌǇŝŶ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞĂƐƐŽĐŝĂƚĞĚǁŝƚŚƚŚĞĨĂĐƚŽƌƐĚĞƐĐƌŝďĞĚ
(data not shown). 
 
The influence eaffect ŽĨǀŽůƵŵĞŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞƐĞĞŶďǇĐůŝŶŝĐŝĂŶƐƉĞƌǇĞĂƌǁĂƐĂůƐŽĞǆĂŵŝŶĞĚ
and assessed using Kruskal-Wallis test. (Figure 3). Although the majority of clinicians across all 
subgroups (by volume) would recommend surgery in the presence of all of the factors listed, 
ĐůŝŶŝĐŝĂŶƐǁŚŽƐĞĞŚŝŐŚǀŽůƵŵĞƐŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞǁĞƌĞƐŝŐŶŝĨŝĐĂŶƚůǇůĞƐƐůŝŬĞůǇƚŽƌĞĐŽŵŵĞŶĚ
surgery in patients with a large goitre (p<0.001) and in women intending to start a family 
(p=0.004).  
 
Clinicians were then asked what they thought influenced patients ? choices regarding their 
treatment. The majority of clinicians agreed that most of the factors suggested would influence 
ƉĂƚŝĞŶƚĚĞĐŝƐŝŽŶƐĞǆĐĞƉƚĨŽƌ ?ƐůŽǁ ?ƵŶƉƌĞĚŝĐƚĂďůĞƌĞƐƉŽŶƐĞƚŽƌĂĚŝŽŝŽĚŝŶĞ ?. The responses to this 
question were compared in subgroups defined by specialty (Figure 24) and assessed with Mann-
Whitney U test. Surgeons were less likely to agree that factors that related to surgery  ? fear of 
surgery (p=0.001) and complications of general anaesthesia (p=0.037)  ? influenced patient 
decisions with regards to definitive management. Endocrinologists were more likely to strongly 
disagree that the slow or unpredictable response with radioiodine (p<0.001) was a factor that 
patients may consider.  
 
The survey also examined how clinical speciality may influence the risks mentioned to patients 
ǁŚĞŶĚŝƐĐƵƐƐŝŶŐĚĞĨŝŶŝƚŝǀĞŵĂŶĂŐĞŵĞŶƚŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞŝ.e. surgery or radioactive iodine. As 
shown in Table 2, surgeons were more likely to quote a higher rate of failure (p=0.005) or relapse 
(p=0.003) with radioiodine and the risk of long-term hypocalcaemia (p=0.016) than physicians. 
 
Table 2. Risks of failure and complications of treatments as quoted by clinicians by specialty 
 Responses 
(n) 
All clinicians 
 ? median % 
(range) 
Physicians  ? 
median % 
(range) 
Surgeons  ? 
median % 
(range) 
P value (Mann-
Whitney U test) 
Relapse following 
ATD  
132 50.0  
(10.0-70.0) 
50.0  
(10.0-70.0) 
50.0  
(12.5-70.0) 
0.151 
Failure rate of first 
dose radioiodine  
123 10.0  
(0.9-60.0) 
10.0 
(0.9-60.0) 
20.0  
(4.5-50.0) 
0.005 
Relapse rate 
following first dose 
radioiodine  
109 5.0 
(0.0-50.0) 
5.0  
(0.0-33.3) 
8.75  
(1.5-50.0) 
0.003 
Risk of permanent 
laryngeal nerve 
injury 
131 1.0 
(0.0-8.0) 
1.0  
(0.4-5.0) 
1.0  
(0.0-8.0) 
0.272 
Risk of long-term 
hypocalcaemia 
131 4.5 
(0.2-30.0) 
4.0 
(0.2-30.0) 
5.0  
(0.5-15.0) 
0.016 
 
 
When questioned about what risks were quoted to patients when discussing surgery and 
radioactive iodine, answers varied widely. The main complications of radioiodine mentioned to 
patients were hypothyroidism, exacerbation of thyroid eye disease and radiation protection 
issues. When discussing surgical treatment, the risks discussed frequently were scarring, 
hypothyroidism and infection. Only 18.9% said they would mention risk of voice damage and only 
12.6% mentioned risk of post-operative hypocalcaemia. 
 
Clinicians were also asked on the rates of different definitive treatment taken up by their patients. 
Their responses by specialty and geography are displayed in Table 3 and Figure 35 respectively. 
Table 3 shows a statistically significant difference in the perceived uptake of treatment between 
surgeons and physicians. However, it should be noted that there were only 109 responses to this 
question, of which only eight were surgeons. 
 
Table 3. Rates of patients who undergo second-round antithyroid drugs, radioiodine and surgery 
as perceived by UK clinicians 
 Total  ? 
median % 
(range) 
Physicians  ? 
median % 
(range) 
Surgeons  ? 
median % 
(range) 
P value 
(Mann-
Whitney U 
test) 
Second 
round 
antithyroid 
drugs 
25.0 
(0.0-96.0) 
20.0  
(0.0-96.0) 
25.0 
(0.0-80.0) 
0.815 
Radioiodine 50.0  
(4.0-97.0) 
50.0 
(0.0-97.0) 
22.5 
(10.0-80.0) 
0.015 
Surgery 10.0 
(0.0-100.0) 
10.0 
(0.0-100.0) 
27.5 
(10.0-90.0) 
0.018 
 
 
When evaluated by region, the use of radioiodine did not appear to significantly vary between 
regions, but the choice of surgery and second round antithyroid therapy did. The vast majority of 
patients in Wales appeared to undergo radioiodine for relapsed Graves ?ĚŝƐĞĂƐĞ, while this was 
least frequent in Scotland. Of the three options, surgery is used least frequently in most regions, 
particularly in Northern Ireland and Wales. The most frequent use of surgery is in the South East 
and East Midlands (25%). The significant differences in choice of second-round antithyroid 
treatment were demonstrated by the uncommon use in Wales (2%) compared to > 10% in many 
parts of England and > 50% in Scotland.  
 
The final question asked the clinicians to decide treatment they would have if they were suffering 
from uncomplicated relapsed 'ƌĂǀĞƐ ? disease. The majority (n=95) chose radioiodine in this 
situation; 37 chose antithyroid drugs and 17 surgery (of which 12 were surgeons). Seven were 
unsure, whilst two preferred not to say (Figure 46).  Speciality was found to influence the choice of 
therapy in favour of the treatment in which the individual was involved (Pearson Chi-square 
p=0.001). Gender, volume and experience (median number of years since graduation) did not 
ĂƉƉĞĂƌƚŽŝŶĨůƵĞŶĐĞƚŚĞŝƌĚĞĐŝƐŝŽŶ ?WĞĂƌƐŽŶ ?ƐŚŝ-ƐƋƵĂƌĞƚĞƐƚƉA䄃? ? ? ? ? ?WĞĂƌƐŽŶ ?ƐŚŝ-square test 
ƉA䄃? ? ? ? ? ?ĂŶĚ^ƉĞĂƌŵĂŶ ?ƐĐŽƌƌĞůĂƚŝŽŶĐŽĞĨĨŝĐŝĞŶƚƌŚŽA䄃? ? ? ? ? ƉA䄃? ? ? ? ?ƌĞƐƉĞĐƚŝǀĞůǇ ? ? 
 
 
  
DISCUSSION 
Current practices in the definitive treatment of Graves ? disease in the UK are influenced by 
ƉĂƚŝĞŶƚƐ ?ĐŚŽŝĐĞ ?ƐŽĐŝĂůĐŝƌĐƵŵƐƚĂŶĐĞƐĂŶĚĐůŝŶŝĐŝĂŶƐ ?ĞǆƉĞƌŝĞŶĐĞ ?dŚŝƐŝƐĞƐƉĞĐŝĂůůǇtrue for relapsed 
'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ? Prior to this survey, these patterns have been explored in Europe[4,6][5,6] USA, 
and worldwide [3] but a detailed evaluation amongst UK consultants has not been performed.  
 
Our survey revealed that the majority of clinicians would routinely start antithyroid medication 
with the aim of inducing remission in an ƵŶĐŽŵƉůŝĐĂƚĞĚ ?ĨŝƌƐƚƉƌĞƐĞŶƚĂƚŝŽŶŽĨ'ƌĂǀĞƐ ? disease. Only 
two physicians and two surgeons would start antithyroid medication as a bridge to definitive 
treatment in all of their patients. The reasons for adopting either of the two approaches in a 
selective manner in subgroups of patients were reviewed in Table 3. Patient preference seems to 
ďĞĂĐŽŵŵŽŶŝŶĨůƵĞŶĐĞŽŶƚŚĞƉŽůŝĐǇŽĨƵƐŝŶŐĂŶƚŝƚŚǇƌŽŝĚĚƌƵŐƐŝŶŶĞǁůǇĚŝĂŐŶŽƐĞĚ'ƌĂǀĞƐ ?
disease as a bridge to definitive treatment. Comorbidity has also been quoted as a reason, which is 
similar to another UK-based survey on the use of radioiodine[5][4]. This is reasonable given the 
relative need for more rapid and effective treatment of hyperthyroidism in some patients with 
cardiac comorbidity which has the potential to lead to heart failure and sudden cardiac death[8]. 
Large goitre was also considered as an indication for the early adoption of definitive treatment in 
other surveys[4,5]. The American Thyroid Association and American Association of Clinical 
Endocrinologists support using antithyroid medication as a bridge to definitive therapy in 
compressive/symptomatic goitres or goitres over 80 g[9]. Older age as a reason for using 
antithyroid drugs as a bridge to definitive treatment is debatable. Surveys have found a relatively 
greater preference for definitive treatment (primarily radioiodine) in the elderly[4,5]. In contrast, 
American guidelines suggest that antithyroid drugs should be favoured in older age, although this 
has been described in the context of risk of surgical complications[9]. Klein et al highlights that 
older patients are more likely to have more cardiac comorbidities, and are less likely to revert back 
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to sinus rhythm with treatment of hyperthyroidism[8]. They therefore suggest that more effective 
control over thyrotoxicosis may be preferable to trial of antithyroid medication treatment that has 
a potential relapse rate of approximately 60-70%[10].  
 
This survey has found that surgery is the preferred option for the majority of consultants in 
ƌĞůĂƉƐĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞĐŽŵƉůŝĐĂƚĞĚďǇƚŚĞƉƌĞƐĞŶĐĞŽĨĂŶǇŽĨƚŚĞĐůŝŶŝĐĂůĂŶĚƐŽĐŝĂůĨĞĂƚƵƌĞƐ
described (Table 3). Mild eye disease may be an exception to this trend - 42.7% have a slight or 
strong preference for surgery, and 47.1% were either unsure or had no preference.  This survey 
was different to other studies in that it looked predominantly at factors influencing treatment of 
ƌĞĐƵƌƌĞŶƚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ ?ƌĂƚher than at initial presentation. Although recurrence was described 
in Burch and Vaidya et al[3,5], factors exploring choice of treatment in those studies were in 
relation to initial presentation. Escobar-Jimenez et al[4] looked at recurrence after previous ATD 
and surgery as well as that complicated by pregnancy. Certain findings were comparable across 
these previous studies. Eye disease influences choice away from radioiodine[3,5]; however if eye 
disease is inactive, 46% of clinicians would feel comfortable treating with radioiodine with the 
addition of steroids[5]. This is similar to the results of our survey. Large goitre was more often 
ƚƌĞĂƚĞĚǁŝƚŚƐƵƌŐĞƌǇŝŶƚŚĞŝŶŝƚŝĂůƉƌĞƐĞŶƚĂƚŝŽŶŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞŝŶ^ƉĂŝŶ ?&ŽƌƉƌĞŐŶĂŶƚƉĂƚients 
with relapse, antithyroid medication was the preferred option for the vast majority of patients[4]. 
In our survey, in which antithyroid medication was not an option, 73% had a strong surgical 
preference for surgery in pregnant patients. 
 
The majority of consultants considered that complications of surgery or anaesthesia and fear of 
surgery could influence patients in their decision, although surgeons were less likely to agree that 
this was the case (p=0.037 and p=0.001 respectively). 80.8% of all consultants agreed that the 
ƌĂĚŝĂƚŝŽŶƌŝƐŬƚŽĐŚŝůĚƌĞŶĂŶĚŽƚŚĞƌǀƵůŶĞƌĂďůĞƉĞŽƉůĞǁĂƐůŝŬĞůǇƚŽŝŶĨůƵĞŶĐĞƚŚĞƉĂƚŝĞŶƚ ?ƐĚĞĐŝsion 
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for definitive therapy. Fear of radioiodine with regards to cancer, and slow or unpredictable 
response with radioiodine was also considered to be influential, although to a lesser extent.  
 
Although preference for recommending definitive treatment option in patients with relapsed, but 
ƵŶĐŽŵƉůŝĐĂƚĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞǁĂƐŶŽƚĞǆƉůŽƌĞĚ ?ƚŚĞƉĞƌƐŽŶĂůƉƌĞĨĞƌĞŶĐĞŽĨĐŽŶƐƵůƚĂŶƚƐƐƵƌǀĞǇĞĚ
was examined. 60.5% would undergo radioiodine as their preferred therapy choice of therapy. The 
significant influence of speciality on the preference (p<0.001) provides an interesting insight into 
personal choice of treatment. Only 4.6% of endocrinologists would prefer to have surgery, 
compared to 24.5% of surgeons. It needs to be emphasised that the scenario specifically excluded 
factors that may influence choice of treatment and that these preferences may be different in the 
presence of the variables that have been explored previously.   
 
The perceived numbers of patients who undergo the three treatments following relapse (Table 3) 
shows a significant difference in treatment pathways across the UK. Radioiodine is considered to 
be used in 50.0% (median; range 4.0-97.0) of cases of relapse; second round antithyroid 
medication is used by 25.0% (0.0-96.0) and surgery in 10.0% (0.0-100.0). Preference for 
ƌĂĚŝŽŝŽĚŝŶĞŝŶƌĞůĂƉƐĞĚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞŝƐĂůƐŽŝůůƵƐƚƌĂƚĞĚŝŶŽƚŚĞƌƐƚƵĚŝĞƐincluding physicians in 
the UK [5] and mainland Europe[4]. Seven consultants said that less than 5% of patients would 
undergo a second round treatment with antithyroid drugs in their centre (an additional four did 
not provide an answer for antithyroid drugs but a total of 100% was provided for radioiodine plus 
surgery). In contrast, eleven said that 80% or more would choose antithyroid drugsthis option. The 
total of all answers provided in these questions had a total of 90-110%, (where some 
ŝŶƚĞƌƉƌĞƚĂƚŝŽŶŽĨƌĂŶŐĞƐŽƌ ?ŵŽƌĞ ?ůĞƐƐƚŚĂŶ ?ĂŶƐǁĞƌƐŵĂǇĂĐĐŽƵŶƚĨŽƌĚŝĨĨĞƌĞŶĐĞƐ ? ?ŽƚŚĞƌƚŚĂŶ
from one responder. This establishes that the majority of consultants interpreted the question 
correctly and considered second round antithyroid drug treatment to be a separate regime from 
that which is used to prepare patients for radioiodine or surgery. The use of radioiodine did not 
differ between the regions (p=0.125), while repeat treatment with antithyroid drugs (p=0.022) and 
surgery (p=0.011) differed significantly. This is illustrated in Figure 5. 
 
Both endocrinologists and surgeons consider that 50.0% (median; range 10.0-70.0) of patients will 
relapse following antithyroid medication. However, widely ranging rates of failure and relapse 
with radioiodine, permanent laryngeal nerve injury and long-term hypocalcaemia were quoted by 
clinicians across the UK (Table 2). Risk of permanent laryngeal nerve injury did not differ by 
specialty, and was considered to be around 1.0% (0.0-8.0). Two surgeons considered that relapse 
following radioiodine was ten times higher than the median value provided by all consultants. 
Other than for relapse following antithyroid medication, theall highest values stated by 
consultants were more than six times the median value. Although the surgical risks were described 
ĂƐ ?ƉĞƌŵĂŶĞŶƚ ? ?ĐŽŶƐƵůƚĂŶƚƐŵĂǇŚĂǀĞĂƐƐƵŵĞĚƚŚĂƚƚŚŝƐǁĂƐĨŽƌ ?ƚƌĂŶƐŝĞŶƚ ?ŽƌƚŽƚĂůǀĂůƵĞƐ ?dŚĞ
differences in the perceptions of risk for complications ?ĨĂŝůƵƌĞĂŶĚƌĞůĂƉƐĞŝŶ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞ
treatments across the UK strengthen the case for the need for empiric data from the UK 
population. 
 
dŚĞĐůŝŶŝĐŝĂŶ ?ƐƐƉĞĐŝĂůity was strongly associated with personal choice and preference for specific 
treatments in the presence of specific patient- and disease-related factors. Surgeons had more 
positive views of surgery.  
 
Other interesting findings from this study were that female clinicians were more likely to 
recommend surgery in the presence of severe eye disease (p=0.017) and lactation (p=0.008); and 
high volume consultants were less likely to strongly recommend surgery in patients with a large 
goitre (p<0.001) or those intending to start a family (p=0.004). Given the exploratory nature of this 
study, these should only be considered as preliminary findings. However, it is clear that clinician 
related factors can significantly influence treatment recommendations. 
 
As with surveys in general, there are a few limitations, which may influence the conclusions of this 
study. Despite piloting the study locally, there was a suggestion of misinterpretation of some of 
the questions by a number of respondents from the comments in the free text area. In addition, 
we asked consultants for their interpretation of practice within their centre, which may not 
correlate with actual practice. Occasionally, the respondents used ratios, ranges, and text answers 
for questions requiring percentages. In these cases, ǁĞƵƐĞĚĂƐĞƚŽĨ ?ƌƵůĞƐ ? to attempt to 
summarise the responses. However, this may have introduced bias in interpretation of the 
answers. The same limitation applies to the attempt to group some of the responses into themes. 
The response rate is not ascertainable given the overlap of membership between the three 
societies surveyed. The response rate may have been higher with posted questionnaires, or with a 
financial incentive; however this was not logistically or financially feasible. Given the size of the 
memberships emailed, the number of responses obtained seems adequate.  
 
In conclusion, within ƚŚĞh< ?ŵŽƐƚĐůŝŶŝĐŝĂŶƐƚƌĞĂƚŶĞǁŽŶƐĞƚ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞǁŝƚŚĂĐŽƵƌƐĞŽĨ
antithyroid medication in the hope of achieving remission. Approximately 50% of patients are 
thought to have a relapse following treatment. Definitive treatment in the form of radioiodine is 
the preferred choice for 50% of patients (median; range 4.0-97.0); however clinicians are inclined 
to recommend surgery in the presence of moderate eye disease, large goitre, cold nodule, 
patients with children at home or young female patients intending to start a family. In the context 
of pregnancy, lactation, or severe eye disease, the majority of consultants would strongly 
recommend surgical treatment to their patients. The perceived complication and relapse rates of 
therapy varied significantly across consultants that responded to the questionnaire. Empiric data 
on failure and complication rates in the UK population is required. Discussion about the need for 
national guidelines ŽŶƚŚĞŵĂŶĂŐĞŵĞŶƚŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞƐŚŽƵůĚĂůƐŽďĞĐŽŶƐŝĚĞƌĞĚ. 
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Figures 
Figure 1. Comparison of preferences of physicians and surgeons for surgery or radioiodine in the 
ƚƌĞĂƚŵĞŶƚŽĨ'ƌĂǀĞƐ ?ĚŝƐĞĂƐĞŝŶƚŚĞƉƌĞƐĞŶĐĞŽĨƐƉĞĐŝĨŝĐĐůŝŶŝĐĂůĂŶĚƐŽĐŝĂůĨĂĐƚŽƌƐ ? ?DĂŶŶ-Whitney 
U test) 
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Figure 3. Comparison of preferences for surgery or radioiodine of clinicians stratified by volume of 
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Figure 2.  Comparison of the perceptions of factors that influence patient decision in regards to 
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Figure 4. Personal treatment choice of physicians and surgeons for uncomplicated Graves' disease 
at relapse 
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